Danish Head And Neck Cancer Group

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Phase 3

Completed

Conditions: Cancer of the Head and Neck

Interventions: Radiation: Radiotherapy
Drug: Zalutumumab

First Posted Date: 2007-07-04

Last Posted Date: 2016-11-25

Lead Sponsor: Danish Head and Neck Cancer Group

Target Recruit Count: 619

Registration Number: NCT00496652

Locations: 🇩🇰
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy